Literature DB >> 11711784

Severe hepatic involvement in visceral larva migrans.

M Hartleb1, K Januszewski.   

Abstract

Because of its anatomical position, the liver may be involved in many protozoan and helminthic gastrointestinal infections. Visceral larva migrans caused by Toxocara canis is rarely taken into account in adult patients with cholestatic syndrome, especially when liver disease is not associated with hypereosinophilic reaction. We report on a 74-year-old immunocompetent woman who presented with fever, bronchospasm, erythema nodosum, weight loss and progressive jaundice. A liver biopsy showed caseating granulomatous hepatitis with secondary portal fibrosis and paucity of interlobular bile ducts. A step-by-step search for aetiological factors led us to a diagnosis of toxocariasis (positive enzyme-linked immunosorbent assay IgG test). An excellent clinical response to combined treatment with steroid and diethylcarbamazine, and a reduction in the antibody level against T. canis supported the diagnosis. Computed tomography and laparoscopy demonstrated multiple small mass lesions and fibrous perihepatitis. This report shows that visceral larva migrans may be a cause of prostrating chronic liver disease and should be suspected in every febrile patient with cryptogenic cholestatic hepatitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711784     DOI: 10.1097/00042737-200110000-00020

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  10 in total

1.  Eosinophilic infiltration in Korea: idiopathic?

Authors:  Jae Hoon Lim; Kyung Soo Lee
Journal:  Korean J Radiol       Date:  2006 Jan-Mar       Impact factor: 3.500

Review 2.  Cerebral Toxocariasis: Silent Progression to Neurodegenerative Disorders?

Authors:  Chia-Kwung Fan; Celia V Holland; Karen Loxton; Ursula Barghouth
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 3.  Human gastrointestinal nematode infections: are new control methods required?

Authors:  Gillian Stepek; David J Buttle; Ian R Duce; Jerzy M Behnke
Journal:  Int J Exp Pathol       Date:  2006-10       Impact factor: 1.925

Review 4.  Toxocariasis: clinical aspects, epidemiology, medical ecology, and molecular aspects.

Authors:  Dickson Despommier
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

5.  Toxocara Awareness Among Medical Practitioners in Saudi Arabia.

Authors:  Fakhreldin M Omer; Nabil J Awadalla; Safar Abadi Alsaleem; Mohammed Abadi Alsaleem; Riyad A Moosa; Mohamed A Alqahtani; Abdulmageed A Asiri; Ebtesam M Alahmari; Amal N Alqahtani; Ahmed A Mahfouz
Journal:  Ecohealth       Date:  2021-05-20       Impact factor: 3.184

6.  Significance of Charcot Leyden crystals in hepatic aspirates.

Authors:  Vatsala Misra; Sharmistha Debnath; Sri P Misra; Premala A Singh
Journal:  J Cytol       Date:  2009-04       Impact factor: 1.000

7.  Hepatic larva migrans presenting with upper gastrointestinal haemorrhage: A case report.

Authors:  Ranjan K Patel; Shruti Mittal
Journal:  SA J Radiol       Date:  2021-11-26

8.  Eosinophilic granulomatous gastrointestinal and hepatic abscesses attributable to basidiobolomycosis and fasciolias: a simultaneous emergence in Iraqi Kurdistan.

Authors:  Hemmin A Hassan; Runnak A Majid; Nawshirwan G Rashid; Bryar E Nuradeen; Qalandar H Abdulkarim; Tahir A Hawramy; Rekawt M Rashid; Alton B Farris; Jeannette Guarner; Michael D Hughson
Journal:  BMC Infect Dis       Date:  2013-02-20       Impact factor: 3.090

9.  Hepatic visceral larva migrans, a resilient entity on imaging: Experience from a tertiary liver center.

Authors:  Shalini Thapar Laroia; Archana Rastogi; Chhagan Bihari; Ajeet Singh Bhadoria; Shiv Kumar Sarin
Journal:  Trop Parasitol       Date:  2016 Jan-Jun

Review 10.  Toxocariasis: a silent threat with a progressive public health impact.

Authors:  Jia Chen; Quan Liu; Guo-Hua Liu; Wen-Bin Zheng; Sung-Jong Hong; Hiromu Sugiyama; Xing-Quan Zhu; Hany M Elsheikha
Journal:  Infect Dis Poverty       Date:  2018-06-13       Impact factor: 4.520

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.